Excessive activation of the alternative complement pathway in autosomal dominant polycystic kidney disease

Journal of Internal Medicine

Volumn 276, Issue 5, 2014, Pages 470-485

  Su, Z ^a,g   Wang, X ^a   Gao, X ^a   Liu, Y ^b   Pan, C ^c   Hu, H ^a   Beyer, R P ^d   Shi, M ^c   Zhou, J ^e   Zhang, J ^c   Serra, A L ^b,f   Wuthrich R P ^b,f   Mei, C ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF ZURICH   (Switzerland)

^c UNIVERSITY OF WASHINGTON   (United States)

^d UNIVERSITY OF WASHINGTON   (United States)

^e BRIGHAM AND WOMEN S HOSPITAL   (United States)

^f UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^g THE FIRST AFFILIATED HOSPITAL OF WENZHOU MEDICAL UNIVERSITY   (China)

Author keywords

Autosomal dominant polycystic kidney disease; Complement; Complement inhibitor; Glycoproteomics; Urine

Indexed keywords

ALTERNATIVE COMPLEMENT PATHWAY C3 C5 CONVERTASE; CD59 ANTIGEN; COMPLEMENT COMPONENT C9; CREATININE; DECAY ACCELERATING FACTOR; KI 67 ANTIGEN; ROSMARINIC ACID; TAMOXIFEN; COMPLEMENT; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C4;

ADULT; ANTIGEN ANTIBODY COMPLEX; ARTICLE; CELL PROLIFERATION; CHRONIC KIDNEY FAILURE; CLINICAL ARTICLE; COMPLEMENT ALTERNATIVE PATHWAY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE COURSE; ECHOGRAPHY; EPITHELIUM CELL; FEMALE; GENE MUTATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INFLAMMATORY CELL; KIDNEY BIOPSY; KIDNEY CORTEX; KIDNEY POLYCYSTIC DISEASE; MALE; MOUSE; NONHUMAN; PATHOGENESIS; RAT; SCREENING TEST; UREA NITROGEN BLOOD LEVEL; URINE SAMPLING; WESTERN BLOTTING; ANIMAL; DRUG EFFECTS; FIBROSIS; IMMUNOLOGY; KIDNEY; KNOCKOUT MOUSE; METABOLISM; MIDDLE AGED; PATHOLOGY; URINE;

ADULT; ANIMALS; CELL PROLIFERATION; COMPLEMENT C3; COMPLEMENT C4; COMPLEMENT C9; COMPLEMENT FACTOR B; COMPLEMENT PATHWAY, ALTERNATIVE; COMPLEMENT SYSTEM PROTEINS; DISEASE PROGRESSION; EPITHELIAL CELLS; FIBROSIS; HUMANS; KIDNEY; MICE, KNOCKOUT; MIDDLE AGED; POLYCYSTIC KIDNEY, AUTOSOMAL DOMINANT; RATS;

EID: 84911396742     PISSN: 09546820     EISSN: 13652796     Source Type: Journal    
DOI: 10.1111/joim.12214     Document Type: Article

References (18)

1. The International Polycystic Kidney Disease Consortium. Polycystic kidney disease: the complete structure of the PKD1 gene and its protein. The International Polycystic Kidney Disease Consortium. Cell 1995; 81: 289-98.
2. Mochizuki T, Wu G, Hayashi T et al. PKD2, a gene for polycystic kidney disease that encodes an integral membrane protein. Science 1996; 272: 1339-42.
3. Patel V, Chowdhury R, Igarashi P. Advances in the pathogenesis and treatment of polycystic kidney disease. Curr Opin Nephrol Hypertens 2009; 18: 99-106.
4. Wuthrich RP, Mei C. Aquaretic treatment in polycystic kidney disease. N Engl J Med 2012; 367: 2440-2.
5. Burtey SJ, Riera M, Fontes M. Overexpression of complement-component genes in Han:SPRD rats a model of polycystic kidney disease. Kidney Int 2008; 73: 1324-5; author reply 5.
6. Lai X, Bacallao RL, Blazer-Yost BL, Hong D, Mason SB, Witzmann FA. Characterization of the renal cyst fluid proteome in autosomal dominant polycystic kidney disease (ADPKD) patients. Proteomics Clin Appl 2008; 2: 1140-52.
7. Pei Y, Obaji J, Dupuis A et al. Unified criteria for ultrasonographic diagnosis of ADPKD. J Am Soc Nephrol 2009; 20: 205-12.
8. Shi M, Bradner J, Bammler TK et al. Identification of glutathione S-transferase pi as a protein involved in Parkinson disease progression. Am J Pathol 2009; 175: 54-65.
9. Hong Z, Shi M, Chung KA et al. DJ-1 and alpha-synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease. Brain 2010; 133: 713-26.
10. Piontek KB, Huso DL, Grinberg A et al. A functional floxed allele of Pkd1 that can be conditionally inactivated in vivo. J Am Soc Nephrol 2004; 15: 3035-43.
11. Zhang J, Goodlett DR, Peskind ER et al. Quantitative proteomic analysis of age-related changes in human cerebrospinal fluid. Neurobiol Aging 2005; 26: 207-27.
12. Takakura A, Contrino L, Beck AW, Zhou J. Pkd1 inactivation induced in adulthood produces focal cystic disease. J Am Soc Nephrol 2008; 19: 2351-63.
13. Cugno M, Zanichelli A, Foieni F, Caccia S, Cicardi M. C1-inhibitor deficiency and angioedema: molecular mechanisms and clinical progress. Trends Mol Med 2009; 15: 69-78.
14. Le Quintrec M, Lionet A, Kamar N et al. Complement mutation-associated de novo thrombotic microangiopathy following kidney transplantation. Am J Transplant 2008; 8: 1694-701.
15. Wang L, Li F, Sun W et al. Concanavalin A-captured glycoproteins in healthy human urine. Mol Cell Proteomics 2006; 5: 560-2.
16. Ghosh D, Krokhin O, Antonovici M et al. Lectin affinity as an approach to the proteomic analysis of membrane glycoproteins. J Proteome Res 2004; 3: 841-50.
17. Li QR, Fan KX, Li RX et al. A comprehensive and non-prefractionation on the protein level approach for the human urinary proteome: touching phosphorylation in urine. Rapid Commun Mass Spectrom 2010; 24: 823-32.
18. Lai ZW, Steer DL, Smith AI. Membrane proteomics: the development of diagnostics based on protein shedding. Curr Opin Mol Ther 2009; 11: 623-31.